ARCHIVES

Drug Development: FDA Grants Breakthrough Therapy Designation To CTL019 in ALL

This article is from The Cancer Letter archive.

Vol. 40 No. 24 | June 11, 2014

Download PDF Visit The Full Archive

Related Articles

Facilities Survey To Include All Institutions With $200,000 Or More in NCI Support

October 5, 1984

Yates Named DRCCA AD To Head Centers, CCOP, Organ Sites: CCOP Workshops Listed

February 26, 1982

Denosumab Demonstrates Superiority Over Zometa For Bone Metastases

August 28, 2009

NCI Would Fund 1,052 Competing Grants In Fy95

February 11, 1994

New Edition Of Book On Cancer Rates, Risks, Available

February 28, 1997

Unique Molecular Profile For Lung Cancer Described

March 31, 2006